Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06864988 · ClinicalTrials.gov registry record · Phase 3
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3 study of Macular Neovascularization Secondary to Age-Related Macular Degeneration, sponsored by 4D Molecular Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT06864988: Recruiting Phase 3 study of Macular Neovascularization Secondary to Age-Related Macular Degeneration, sponsored by 4D Molecular Therapeutics.
NCT06864988 is a Phase 3 study of Macular Neovascularization Secondary to Age-Related Macular Degeneration that is actively recruiting participants, run by 4D Molecular Therapeutics. The registered enrollment target is 480 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06864988, a Phase 3 study of Macular Neovascularization Secondary to Age-Related Macular Degeneration, is actively recruiting participants, sponsored by 4D Molecular Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Conditions Studied
Interventions
- BIOLOGICAL 4D-150 IVT (3E10 vg/eye)
- BIOLOGICAL EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Study Locations (20)
California
- California Retina Consultants - Bakersfield
- Retina Vitreous Associates Medical Group - Beverly Hills
- The Retina Partners - Encino
- Retina Associates of Southern California - Huntington Beach
- Loma Linda University Faculty Medical Clinics - Loma Linda
- Jules Stein Eye Institute - Los Angeles
- Northern California Retina Vitreous Associates - Mountain View
- Gavin Herbert Eye Institute - Orange
- Retina Consultants of San Diego - Poway
- Kaiser Permanente-Riverside Medical Center - Riverside
- Retinal Consultants Medical Group Inc - Sacramento
- Retinal Consultants Medical Group Inc - Sacramento
- Orange County Retina Medical Group - Santa Ana
- California Retina Consultants - Santa Barbara - Santa Barbara
- Bay Area Retina Associates - Walnut Creek
Arizona
- Barnet Dulaney Perkins Eye Center - Phoenix
- Retinal Research Institute, LLC - Scottsdale
Colorado
- University of Colorado, Denver - Aurora
- Retina Consultants of Southern Colorado - Colorado Springs
Arkansas
- Retina Partners of Northwest Arkansas - Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06864988
The ClinicalTrials.gov registry entry for NCT06864988 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower). The listed sponsor is 4D Molecular Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Neovascularization Secondary to Age-Related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which 4D-150 IVT (3E10 vg/eye) is the first listed.
NCT06864988 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT06864988 about?
NCT06864988 is a clinical study titled "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration". A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
What is the current status of trial NCT06864988?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-03-03. Estimated completion is 2028-06.
What conditions does trial NCT06864988 study?
This clinical trial studies the following conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration.
What interventions are being tested in trial NCT06864988?
The interventions under investigation include: 4D-150 IVT (3E10 vg/eye) (BIOLOGICAL), EYLEA® (aflibercept) Injection 2 mg (0.05mL) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06864988?
This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06864988 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001625 · 480 participants
Methods for Measuring Insulin Sensitivity
- NCT00002848 · 480 participants · NA
Group Therapy Compared With Educational Materials in Patients With Prostate Cancer
- NCT00005915 · 480 participants
A Comparison of Two Anti-HIV Treatment Plans
- NCT00051727 · 480 participants · Phase 2
Prevention of School Dropout for Mexican American Adolescents
Similar registry start date
- NCT05684068 · started 2028-08 · NA
Dimensional Changes: Randomized Clinical Trial
- NCT07167953 · started 2028-08 · NA
The Spiral MRI Study
- NCT07215013 · started 2028-07 · NA
Acoustic Resonance Therapy for Treating Empty Nose Syndrome
- NCT07443332 · started 2028-07 · NA
Culturally Adapted Contingency Management
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.